Arcellx

Arcellx(ACLX)

REDWOOD CITY, CA
Biotechnology1 H-1B visas (FY2023)

Focus: Adaptive Immune Cell Therapies

Arcellx is a life sciences company focused on Adaptive Immune Cell Therapies.

Oncology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Clinical Trials (1)
NCT05457010Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Phase 1
Phase 1
Phase 1
Clinical Trials (1)
NCT06626919A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Phase 1
anitocabtagene-autoleucel
Multiple Myeloma
Phase 2
Anitocabtagene Autoleucel
Multiple Myeloma
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 2 clinical trials
H-1B (2023): 1 approval
SEC Filings: 2 available

Financials (FY2025)

Revenue
$110M0%
R&D Spend
$134M(121%)11%
Net Income
-$71M
Cash
$106M

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub